Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325493 · ClinicalTrials.gov registry record · Phase 4
Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia
A Phase 4 study, sponsored by Julia Finkel.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT01325493 is a Phase 4 study that has completed, run by Julia Finkel. The registered enrollment target is 54 participants.
The verdict
NCT01325493, a Phase 4 study, has completed, sponsored by Julia Finkel.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to: 1\. Establish whether ketamine can decrease opioid consumption and modulate the onset of opioid tolerance and prevent opioid-induced hyperalgesia in pediatric subjects, ages 10 years to 18 years, undergoing posterior spinal fusion and instrumentation.
Interventions
- DRUG Ketamine
- DRUG Normal Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01325493
The ClinicalTrials.gov registry entry for NCT01325493 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Julia Finkel, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT01325493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01325493 about?
NCT01325493 is a clinical study titled "Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia". The purpose of this study is to: 1\. Establish whether ketamine can decrease opioid consumption and modulate the onset of opioid tolerance and prevent opioid-induced hyperalgesia in pediatric subjects, ages 10 years to 18 years, undergoing posterior spinal fusion and instrumentation.
What is the current status of trial NCT01325493?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2010-01. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01325493?
The interventions under investigation include: Ketamine (DRUG), Normal Saline (DRUG).
Who is sponsoring clinical trial NCT01325493?
This trial is sponsored by Julia Finkel, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.